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Summary
 
The antiapoptotic protein cellular FLICE (Fas-associated death domain–like IL-1
 
b
 
–converting
enzyme) inhibitory protein (cFLIP) protects cells from CD95(APO-1/Fas)-induced apoptosis
in vitro and was found to be overexpressed in human melanomas. However, cytotoxic T cell–
induced apoptosis, which is critically involved in tumor control in vivo, is not inhibited by
cFLIP
 
 
 
in vitro, as only CD95- and not perforin-dependent lysis is affected. This calls into ques-
tion whether cFLIP is sufficient to allow escape from T cell–dependent immunity. Using two
murine tumors, we directly demonstrate that cFLIP does result in escape from T cell immunity
in vivo. Moreover, tumor cells are selected in vivo for elevated cFLIP expression. Therefore,
our data indicate that CD95-dependent apoptosis constitutes a more prominent mechanism for
tumor clearance
 
 
 
than has so far been anticipated and that blockade of this pathway can result in
tumor escape even when the perforin pathway is operational.
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A
 
poptosis is a carefully controlled suicide program that
serves to dispose of superfluous or unwanted cells (1).
It can be induced by the triggering of specific death recep-
tors, such as CD95(APO-1/Fas) (2). Activation of CD95
can lead to recruitment and activation of caspase-8 (3–6),
which then engages the cell death machinery (7, 8). Several
mechanisms have been proposed over the last few years
that can interfere with death receptor–induced apoptosis
(7, 9). Of these, cFLIP (also called Casper/iFLICE/
FLAME-1/CASH/CLARP/MRIT/usurpin) (9) is proba-
bly the most receptor proximal. Interestingly, cFLIP ex-
pression is increased in human melanomas (references 10
and 11; Medema, J.P., and J. de Jong, unpublished obser-
vations), suggesting that these tumor cells become refractory
to CD95-induced apoptosis.
CTLs play a critical role in the control of tumor growth
(12). They lyse their targets through CD95- as well as per-
forin-dependent pathways (13–15). Although both path-
ways can converge at an early step in the signaling cascade
that leads to target cell apoptosis (16), cFLIP was shown to
only inhibit CD95-dependent and not perforin-dependent
apoptosis (17). In effect, cFLIP overexpression fails to pro-
tect cells from lysis by an effector population consisting of
polyclonal alloreactive CTLs in vitro (17). We obtained
comparable results with tumor-specific CTL clones that
have a defined peptide specificity and Raji, a human Bur-
kitt B cell lymphoma, loaded with the relevant peptide
epitope as target cell (Medema, J.P., and J. de Jong, unpub-
lished observations). Clearly, cFLIP overexpression effi-
ciently blocks the CD95 pathway but does not inhibit
CTL-mediated lysis in vitro.
Here, we set out to analyze whether cFLIP overexpres-
sion can affect the sensitivity of tumor cells to T cell immu-
nity in vivo
 
 
 
and permit tumorigenesis. We employed two
murine tumors whose eradication critically depends on the
CTL response (18, 19). We demonstrate that overexpres-
sion of cFLIP results in their escape from T cell immunity.
Moreover, we show that tumor cells are selected in vivo
for elevated cFLIP expression.
 
Materials and Methods
 
Mice.
 
C57BL/6 perforin
 
2
 
/
 
2
 
 (PKO, H-2
 
b
 
; reference 20; a gift
from Dr. M. van den Broek) and C57BL/6 Kh (B6, H-2
 
b
 
) mice
were bred at TNO-PG (Leiden, The Netherlands). C57BL/6
 
nu/nu
 
(B6 nude, H-2
 
b
 
) mice were obtained from Bomholtgard (Ry,
Denmark).
 
Cells.
 
Adenovirus type 5 E1A plus mutant EJ-
 
ras
 
–transfected
(AR6; reference 19) and MBL2-Fas (MF; reference 20) (a gift
from Dr. M. van den Broek, Zürich, Switzerland) were trans-
fected by electroporation (240 V, 960 
 
m
 
F) with a plasmid encod-
ing murine FLAG-tagged cFLIP under the control of a CMV
promoter (cDNA provided by Dr. J. Tschopp, Lausanne, Swit-
zerland) or a control plasmid. Sam-D
 
b 
 
is a mouse embryo fibro-
blast transfected with a plasmid encoding the E1A epitope cou-
pled to a signal sequence and murine H-2D
 
b
 
 and therefore
presents high levels of the Ad5E1A epitope in the context of 
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H-2D
 
b
 
. CD95L-expressing C57BL/6
 
lpr/lpr
 
 mouse embryo cells
(MECs) were obtained by Ca
 
3
 
(PO
 
4
 
)
 
2
 
 transfection with a plasmid
encoding murine CD95L. Clone 1 was obtained by immunizing
mice with RMA and is specific for an epitope encoded by the
FMR-MuLV gagLeader sequence (CCLCLTVFL). The E1A
(line 5)– and gagLeader (clone 1)–specific CTLs were cultured as
previously reported (16, 19).
 
Cytotoxicity/Apoptosis Assays.
 
Detection of anti-CD95–trig-
gered apoptosis in MF was performed using the Nicoletti assay as
described (21). Cell-mediated cytotoxicity was determined either
by incubating Na
 
51
 
CrO
 
4
 
- or [
 
3
 
H]thymidine-labeled target cells (1 h,
100 
 
m
 
Ci and 4 h, 5 
 
m
 
Ci, respectively) with CTL clones or
CD95L-expressing MECs at different E/T ratios. Release of 
 
51
 
Cr
was determined by collecting the medium after 6 h. Maximum
release was determined by incubation of the labeled cells with 1 M
HCl. [
 
3
 
H]thymidine retention was determined by harvesting the
cells and counting in the presence of scintillation fluid. To de-
grade perforin, CTLs were preincubated for 2 h with 75 nM
concanamycin A (CMA; Sigma Chemical Co.), which was
present throughout the assay (22). E1A-specific CTL response in
vivo
 
 
 
was determined by isolation of splenocytes and subsequent
restimulation with Sam-D
 
b
 
. After 6 d, CTL activity toward Sam-D
 
b
 
was analyzed with 
 
51
 
Cr release.
 
Immunoprecipitation/Western Blot.
 
Cell lysates and immuno-
precipitates were generated as described (6, 21). For immunopre-
cipitations, the polyclonal rabbit anti-FLAG antibody (Zymed
Labs., Inc.) was used. SDS-PAGE and Western blot analysis were
performed using a standard protocol (6, 16, 21) with the anti–
FLAG-M2 antibody (Eastman Kodak Co.). Flow cytometry was
performed as previously described (23) using Jo2–FITC (Phar-
Mingen) and anti–mouse mAb against H-2D
 
b
 
 and H-2K
 
b
 
.
 
Tumor Challenge.
 
AR6 tumors were injected subcutaneously
into 6-wk-old male mice at 2 
 
3
 
 10
 
7 
 
cells
 
 
 
per mouse. Mice were
killed when tumors reached a size 
 
.
 
1,000 mm
 
3
 
. MF tumors
were injected intraperitoneally into 6-wk-old female mice and
were followed by weighing the animals. Mice were killed at
 
.
 
15% weight gain and/or at clear signs of intraperitoneal tumor
growth.
 
Results and Discussion
 
The inability of cFLIP to prevent CTL killing in vitro
makes it questionable whether increased cFLIP expression,
as observed in human melanomas (references 10 and 11;
Medema, J.P., and J. de Jong, unpublished observations),
can protect tumor cells from CTL-mediated cytotoxicity in
vivo and thereby provide a mechanism of tumor escape.
To analyze this directly, we used the murine tumor line
MF. MF is a CD95 transfectant of MBL2 (20), a Moloney
murine leukemia virus–induced lymphoma that can be
controlled in vivo by virus-specific CTLs (18). Due to the
high sensitivity of MF to CD95-induced apoptosis, it is
well suited to testing the potential of cFLIP to modulate
tumorigenicity.
Transfectants of MF were generated either expressing
high levels (MF-FLIP
 
high
 
) or, as a control, very low levels
(MF-FLIP
 
low
 
) of FLAG-tagged cFLIP (Fig. 1 A, inset).
Both lines express identical amounts of MHC class I and
CD95 (data not shown), but only MF-FLIP
 
low
 
 is sensitive
to apoptosis induced by the murine CD95–specific anti-
body Jo2 in vitro
 
 
 
(Fig. 1 A). Overexpression of cFLIP does
 
not affect tumor-specific CTL–induced cytotoxicity (Fig. 1
B). However, when the perforin pathway of this CTL is
blocked by preincubation with CMA, a substance that re-
sults in specific degradation of perforin (22), the sensitivity
of MF-FLIP
 
high
 
 is completely lost, whereas MF-FLIP
 
low
 
killing is only slightly reduced (Fig. 1 B). These data also
indicate that for the MF tumor, cFLIP expression only af-
fects CD95- and not perforin-dependent killing and that
both pathways need to be inhibited for MF to escape from
CTL-induced apoptosis in vitro.
We subsequently set out to analyze the role of perforin-
and CD95-dependent cytotoxicity in vivo.
 
 
 
Injection of 10
 
2
 
MF-FLIP
 
low
 
 cells
 
 
 
into syngeneic PKO mice results in clear-
ance of the tumor cells in the majority of these mice,
whereas injection of the same dose of MF-FLIP
 
high
 
 cells re-
sults in progressive tumor growth (Fig. 1 C). To our
knowledge, this outcome represents the first direct proof
that overexpression of cFLIP enables tumor cells to escape
CD95-dependent cytotoxicity not only in vitro but also in
vivo.
Next we tested whether cFLIP expression also allowed
Figure 1. Increased tumorigenicity of MF cells by expression of cFLIP.
(A) MF cells (20) were tested for their sensitivity to CD95-induced apop-
tosis with the murine CD95–specific antibody Jo2 at increasing concen-
trations. After 16 h, apoptotic nuclei were determined using the Nicoletti
assay (21). Inset shows expression of FLAG-tagged cFLIP, which was im-
munoprecipitated using a rabbit polyclonal anti-FLAG mAb and subse-
quently detected on Western blot with an mAb against FLAG. (B) CTL-
induced DNA fragmentation of MF-FLIPlow (circles) or MF-FLIPhigh
(squares) in a 6-h DNA fragmentation assay using the Moloney virus
gagLeader-specific CTL clone 1, either left untreated (open symbols) or
preincubated for 2 h with CMA (filled symbols). Experiments shown are
representative of at least three performed with similar results. (C) MF cells
were injected intraperitoneally into PKO (filled symbols) or wild-type
mice (open symbols) at 102 and 106 cells, respectively. (D) 103 (filled sym-
bols) or 106 (open symbols) MF cells were injected into nude mice. In
both C and D, squares represent MF-FLIPhigh and circles represent MF-
FLIPlow. 
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these tumor cells to escape destruction by the immune re-
sponse in wild-type mice, in which not only the CD95-
but also the perforin-dependent pathway is functional.
Wild-type mice are far more resistant to MF-FLIP
 
low
 
. In-
jection of up to 10
 
6
 
 of these cells does not efficiently in-
duce tumors (Fig. 1 C), whereas such doses give rise to
progressively growing tumors in PKO mice (data not
shown). This indicates that perforin-dependent killing is an
essential aspect of the immune defense against this tumor,
an observation that is in line with previous observations
(20) and our in vitro data (Fig. 1 B). Nevertheless, we
found that injection of 10
 
6
 
 MF-FLIP
 
high
 
 cells leads to much
higher tumor-take in wild-type mice than injection of the
same number of MF-FLIP
 
low
 
 cells (Fig. 1 C). Importantly,
MF-FLIP
 
low
 
 and MF-FLIP
 
high
 
 are equally efficient in in-
ducing tumor growth in T cell–deficient nude mice (Fig. 1
D). This indicates that overexpression of cFLIP enables MF
to escape from T cell–dependent immunity in immuno-
competent mice. Even in the presence of perforin-depen-
dent cytotoxicity, which increases the resistance of mice to
these tumors and is sufficient to obtain complete lysis in
vitro, the T cell–dependent immune response in vivo is not
adequately equipped to eradicate MF-FLIP
 
high
 
 tumors.
These data underscore the crucial role of CD95-induced
apoptosis in tumor clearance by a physiological T cell re-
sponse and indicate that blockade of the CD95 pathway
can tip the balance in favor of the tumor cells.
Due to the high levels of CD95 on MF, CTL activity
against this line may be skewed toward this pathway.
Therefore, we analyzed the effect of cFLIP on a tumor that
expresses only modest levels of endogenous CD95. Tumor
line AR6 has been generated by transfection of B6 MECs
with the adenovirus type 5 E1A and mutant EJ-
 
ras
 
 onco-
genes. Subcutaneous injection of AR6 results in initial tu-
mor growth, after which the tumor regresses due to an effi-
cient CTL response directed against an epitope encoded by
E1A (19). AR6 expresses low but detectable levels of
CD95 (Fig. 2 A). We transfected AR6 with FLAG-tagged
cFLIP (AR6–FLIP) or as control with vector alone (AR6–
vector) (Fig. 2 B
 
,
 
 inset). Two subclones were selected on
the basis of comparable MHC class I expression, growth ki-
netics, and morphological features in vitro.
 
 
 
AR6–vector is
resistant to Jo2 (anti–murine CD95)–induced apoptosis,
probably due to the low cytotoxic potential of this anti-
body (Medema, J.P., and J. de Jong, unpublished observa-
tion). However, in cocultures with CD95L-expressing
MECs, apoptosis of AR6–vector is induced but AR6–FLIP
is fully resistant (Fig. 2 B). Even though CD95-induced ap-
optosis is completely blocked, we find that cFLIP does not
affect lysis of AR6–FLIP by E1A-specific CTLs (Fig. 2 C).
Inhibition of the CD95 pathway during CTL-induced ap-
optosis by cFLIP is, however, suggested by the partial
cleavage of FLAG-tagged cFLIP in AR6–FLIP (Fig. 2 C,
inset), which has been shown to correlate with resistance
(10, 24).
When injected into nude mice, the AR6 lines display
equal and uncontrolled tumor growth (data not shown). In
contrast, both PKO and wild-type mice can control the
AR6–vector tumor (Fig. 2, D and E). However, compara-
ble to our findings with MF-FLIP
 
high
 
, neither of these
mouse strains is capable of rejecting the cFLIP-overexpress-
ing tumor AR6–FLIP (Fig. 2, D and E). Thus, escape from
T cell–mediated immunity in vivo by cFLIP overexpres-
sion is not limited to tumors with very high CD95 surface
expression.
It is important to note that the AR6–FLIP tumor grows
almost as efficiently in PKO and wild-type mice (Fig. 2, D
and E), which suggests that eradication of this tumor de-
pends almost exclusively on CD95. This observation is not
without precedent, as other murine tumor lines, such as the
T cell lymphoma RMA and the melanoma B16, were
shown to be equally tumorigenic in PKO and wild-type
mice (20). Apparently, clearance of certain tumors does not
critically depend on perforin-based cytotoxicity but can be
achieved by other mechanisms, which obviously include
CD95-induced apoptosis. Importantly, this dependance is
Figure 2. cFLIP renders AR6
cells resistant to CD95-induced
apoptosis. (A) The parental AR6
line was tested for surface CD95
expression using Jo2–FITC in
comparison with MF. (B) Both
AR6 transfectants were analyzed
for their sensitivity to CD95L-
expressing MECs in a 16-h
DNA fragmentation assay at dif-
ferent E/T ratios. Inset shows
expression of tagged cFLIP in
both AR6 lines as detected with
the anti-FLAG antibody, M2.
(C) AR6 lines were incubated with E1A-specific CTLs (line 5) in a 6-h
51Cr-release assay. Experiments shown are representative of at least three
performed with similar results. Inset shows full length and cleaved cFLIP
(anti-FLAG M2) in AR6–FLIP before and after incubation with CTL for
2 h. (D and E) AR6–vector (s) and AR6–FLIP (j) were injected subcu-
taneously (2 3 107) into PKO (D; n = 5) or wild-type (wt) mice (E; n =
10). Survival of the mice is shown at different times after injection. Iden-
tical results were obtained with a separate pair of AR6 transfectants (data
not shown). 
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not determined by a high sensitivity to CD95-induced ap-
optosis, as is clear from the two tumor lines tested here.
Further evaluation is required to determine the relative im-
portance of perforin-dependent cytotoxicity among differ-
ent tumor systems, but these data clearly indicate that
CD95-mediated apoptosis constitutes a highly important
mechanism for tumor clearance even in situations where
the perforin pathway is operational.
Recent findings have suggested that apoptosis of tumor
cells may be required for efficient uptake and cross-presen-
tation of tumor antigens by dendritic cells and therefore
may be essential for priming of effective T cell immunity
(25). To test whether immune escape by AR6–FLIP may
involve prevention of T cell priming rather than escape
from the T cell response, we injected B6 mice simulta-
neously with AR6–FLIP and AR6–vector in either flank.
As expected, most mice were again capable of rejecting the
AR6–vector cells, pointing to the induction of an efficient
immune response. Despite this response, AR6–FLIP tu-
mors in the other flanks of these mice developed progres-
sively, indicating that these cFLIP-expressing tumors are
capable of growing out in the face of an effective antitumor
response (Fig. 3 A). To directly examine whether anti-
tumor CTL immunity is induced in mice challenged with
AR6–vector, AR6–FLIP, or both, we analyzed the CTL
response against the E1A epitope in splenocytes from these
mice. Importantly, comparable E1A-specific CTL immu-
nity was detected in all mice (Fig. 3 B).
Also in the MF model, we obtained evidence that cFLIP
overexpression enables escape from antitumor immunity
rather than preventing the induction of this response. As
shown in Fig. 1 C, a minority of the PKO and wild-type
mice challenged with MF-FLIP
 
low
 
 developed progressively
growing tumors. Intriguingly, isolation of these tumors and
analysis
 
 
 
in vitro showed that the cells had acquired resis-
tance to CD95-mediated apoptosis, which correlates well
with the increased expression of cFLIP in these cells (Fig. 3
C). Moreover, reinjection of such tumor cells revealed that
they are as tumorigenic as MF-FLIP
 
high
 
 (data not shown).
As challenge of nude mice with MF-FLIP
 
low
 
 does not result
in tumors with elevated cFLIP expression (data not
shown), this process requires the selective pressure of the T
cell immune system.
In conclusion, our data show that cFLIP-overexpressing
tumors escape from T cell immunity in vivo despite the
fact that they are efficiently killed in vitro. This apparent
discrepancy is most likely due to limitations of in vitro as-
says, which do not accurately reflect the microenvironment
in the tumor. For instance, in vitro
 
 
 
CTL assays are gener-
ally performed at aphysiological E/T ratios and under con-
ditions that allow prolonged CTL–target interactions that
may give rise to a different killing potential of the CTL. Al-
ternatively, the experimental generation of CTL clones of-
ten favors clones with high affinity, which does not neces-
sarily reflect the response against a tumor in vivo. In
addition, in in vitro assays target cells are often pretreated
with IFN-
 
g
 
 to increase their MHC class I expression and
thereby the avidity of the CTL–target interaction. To-
gether, this may change the specificity of the response. In-
deed, it has been suggested that decreasing the affinity/
avidity of the CTL–target interaction shifts the balance of
CTL-mediated cytotoxicity toward the CD95-dependent
pathway (26–28). Although the exact reason for this dispar-
ity remains to be determined, our data do provide direct
evidence that tumor clearance in vivo critically depends on
the CD95 pathway.
 
 
 
In view of this finding, it is interesting
to note that a plethora of mechanisms has been reported by
which tumors seem to block CD95-induced apoptosis. For
instance, mutation (29) or simply downmodulation of
CD95 (30–33) is found in several tumors. Alternatively, se-
cretion of CD95 decoy receptors (34) could provide a sep-
arate route to escape from CD95-dependent cytotoxicity.
Our findings demonstrate that blockade of the CD95 path-
way, for instance through overexpression of cFLIP as was
found in human melanomas (10, 11), can indeed serve as
an efficient mechanism of immune escape by tumors.
 
We are grateful to Marcus Peter and Peter Krammer for providing the anti–APO-1 antibody, Jürg Tschopp
for the cDNA encoding murine cFLIP and the RAJI cell lines, and Maries van den Broek and Hans Hen-
Figure 3. cFLIP-induced immune evasion is due to CTL resistance.
(A) Tumor growth was analyzed in wild-type mice injected simulta-
neously with AR6–vector (2 3 107) into the left flanks and AR6–FLIP (2 3
107) into the right flanks of mice (n; n = 10). For comparison, mice in-
jected in the right flanks with AR6–FLIP (2 3 107) alone is added (j;
n = 10). Percentage survival of the mice is shown. Death of these mice is
in all cases due to growth of the AR6–FLIP tumor. (B) E1A-specific
CTL response was determined by isolating splenocytes from naive or
from tumor-injected mice 2 wk after tumor challenge (two mice per set-
ting). Restimulated splenocytes were tested for their capacity to lyse E1A-
expressing MECs. Error bars represent SEM. (C) Growing MF-FLIPlow
tumors were isolated (ex vivo) from PKO or wild-type (WT) and were
analyzed for their sensitivity to Jo2-induced apoptosis and for expression
of tagged cFLIP on a Western blot using the anti-FLAG M2 antibody.
This is in comparison with the MF cells that were used for injection (pre-
inj.). CD95 sensitivity is indicated as percentage increase of apoptotic nu-
clei after incubation for 16 h with 1 mg/ml Jo2. 
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